Levemir Penfill (Insulin Detemir)

Insulin detemir binds to insulin receptors on muscle, fat and liver cells, promoting glucose uptake and inhibiting hepatic glucose production. Its fatty‑acid side chain enables reversible binding to albumin, extending its circulation time and delivering a consistent basal insulin effect for up to 24 hours.

The dose of Levemir Penfill is individualized and set by a qualified prescriber based on the patient’s age, weight, renal function, dietary habits and current glycaemic control. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical supervision.

Insulin detemir is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation when the prescriber determines that the benefit outweighs any potential risk.

To place an order, submit an enquiry on the Levemir Penfill product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Levemir Penfill (insulin detemir) offers a prolonged, relatively flat basal profile similar to insulin glargine, but its albumin‑binding mechanism may result in slightly less variability between doses. Both are once‑daily options; choice often depends on patient preference, cost, and individual response as assessed by the treating clinician.

Levemir Penfill should be stored in a refrigerator at 2‑8 °C. Keep the pen in its original carton, protect it from light, and avoid freezing. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which it should be discarded.

Levemir Penfill is administered subcutaneously using the pre‑filled pen. The injection site can be the abdomen, thigh, upper arm or buttock, rotating sites with each dose. Patients should follow the pen’s instructions for dose selection, needle attachment and disposal, and always inject at a 90° angle.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognising early hypoglycaemia signs, carrying glucose sources, and seeking immediate medical attention if a severe reaction occurs.

Levemir Penfill is contraindicated in individuals with a known hypersensitivity to insulin detemir or any of the pen’s excipients. It should also be avoided in patients with severe hypoglycaemia unawareness unless closely supervised, and in those for whom basal insulin therapy is not indicated by their treating physician.